Filtered By:
Condition: Coronary Heart Disease
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 806 results found since Jan 2013.

Poor Long-term Outcomes after Carotid Endarterectomy: A Retrospective Analysis of Two Portuguese Centers.
CONCLUSIONS: Patients continue to have high rates of AMI, MACE and death after CEA. Prior CAD is a risk factor for future AMI, whereas CKD is a significant predictor of MACE and death. Aggressive best medical treatment (BMT) and risk factors modification should be advised in patients with systemic atherosclerosis. PMID: 31251084 [PubMed - as supplied by publisher]
Source: Scandinavian Cardiovascular Journal - June 30, 2019 Category: Cardiology Tags: Scand Cardiovasc J Source Type: research

Statins in stroke.
Conclusion: Treatment with statins prevents ischemic stroke, especially in patients with high cardiovascular risk and established atherosclerotic disease. It seems that both lipid lowering and pleiotropic effects contribute to these effects. PMID: 31218948 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - June 18, 2019 Category: Chemistry Authors: Aznaouridis K, Masoura C, Vlachopoulos C, Tousoulis D Tags: Curr Med Chem Source Type: research

Association of Non-LDL Indices with Recurrent Stroke Risk while on Lipid-Modifying Therapy.
CONCLUSIONS: Compared with the nonuse of LT, there may be a hierarchy of residual vascular risk after stroke by non-LDL type and target, while on LT. Particularly, stroke patients with low HDL-C levels on LT may benefit from additional therapeutic strategies to improve their outcomes. PMID: 31189759 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - June 15, 2019 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis
This study determine the relative treatment effects of NST on fatal and nonfatal CV events among statin-treated patients. Methods A network meta-analysis based on a systematic review of randomized controlled trials (RCTs) comparing non-statin lipid-modifying agents among statin-treated patients was performed. PubMed, EMBASE, CENTRAL, and Clinicaltrial.gov were searched up to April 10, 2018. The primary outcomes were CV and all-cause mortalities. Secondary CV outcomes were coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), any stroke, and coronary revascularization. Risks of discontinuations were ...
Source: Frontiers in Pharmacology - May 21, 2019 Category: Drugs & Pharmacology Source Type: research

New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches
Conclusions In recent years, there have been many advances in the understanding of the molecular basis for vascular involvement in APS, but many areas need to be further investigated, in particular the association between altered genetic/epigenetic profiles, autoantibodies and clinical manifestations, and the effectiveness of new therapeutic strategies. It would be interesting to apply next generation sequencing technologies like RNA-Seq along with GWAS to screen both, the gene profile and the whole transcriptome of large cohorts of primary APS patients, in order to reveal the mutations/polymorphisms, post-transcriptiona...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Asymptomatic Carotid Stenosis Is Associated With Circadian and Other Variability in Embolus Detection
Conclusions: Embolism associated with asymptomatic carotid stenosis shows circadian variation with highest rates 4–6 h before midday. This corresponds with peak circadian incidence of stroke and other vascular complications. These and ASED Study results show that monitoring frequency, duration, and time of day are important in ES detection. Introduction Transcranial Doppler (TCD) detected microembolism in the ipsilateral middle cerebral artery (MCA) may help stratify the risk of stroke and other arterial disease complications in persons with advanced (≥60%) asymptomatic carotid stenosis. If so, this t...
Source: Frontiers in Neurology - April 15, 2019 Category: Neurology Source Type: research

Nrf2 as a Potential Mediator of Cardiovascular Risk in Metabolic Diseases
Conclusion Activation of the Nrf2-dependent antioxidant system plays an important role in cell defense against oxidative stress damage, whereas the insufficiency of the Nrf2 system is associated with multiple aspects of the genesis and progression of metabolic diseases, posing a great risk to the cardiovascular system (Figure 1). The systemic increase of Nrf2 activity by several activators may be beneficial in the treatment of metabolic diseases. In addition, selective upregulation of Nrf2 genes may represent a potential therapy in obesity, diabetes and atherosclerosis. Looking to the future, experimental research that el...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality: An Individual-Level Pooled Analysis of 30 Cohort Studies.
CONCLUSIONS: In pooled global analyses, higher in vivo circulating and tissue levels of LA and possibly AA were associated with lower risk of major cardiovascular events. These results support a favorable role for LA in CVD prevention. PMID: 30971107 [PubMed - as supplied by publisher]
Source: Circulation - April 10, 2019 Category: Cardiology Authors: Marklund M, Wu JHY, Imamura F, Del Gobbo LC, Fretts A, de Goede J, Shi P, Tintle N, Wennberg M, Aslibekyan S, Chen TA, de Oliveira Otto MC, Hirakawa Y, Eriksen HH, Kröger J, Laguzzi F, Lankinen M, Murphy RA, Prem K, Samieri C, Virtanen J, Wood AC, Wong K Tags: Circulation Source Type: research

Fibroblast growth factor 21: a role in cardiometabolic disorders and cardiovascular risk prediction?
In this issue of Metabolism, Ong et al [1] report that fibroblast growth factor 21 (FGF21) levels could predict major cardiovascular (CV) events (MCVE) in statin-treated patients with stable coronary heart disease (CHD) using data from the Treating to New Targets (TNT) trial (n  = 10,001; median follow-up = 4.9 years) [2]; MCVE were defined as a composite of CHD death, cardiac arrest, fatal or non-fatal stroke and non-fatal myocardial infarction (MI). In the Ong et al study [1], 1996 patients with plasma FGF21 concentrations available at baseline were analyzed; 1 835 of them had also FGF21 measurements at the 1-year timepoint.
Source: Metabolism - Clinical and Experimental - January 16, 2019 Category: Biomedical Science Authors: Niki Katsiki, Christos Mantzoros Source Type: research

Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Conclusion: The price of alirocumab would have to be reduced considerably to be cost-effective. Because substantial reductions already have occurred, we believe that timely, independent cost-effectiveness analyses can inform clinical and policy discussions of new drugs as they enter the market. Primary Funding Source: University of California, San Francisco, and Institute for Clinical and Economic Review. PMID: 30597485 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - January 1, 2019 Category: Internal Medicine Authors: Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K Tags: Ann Intern Med Source Type: research

Comparative Effectiveness of Combination Therapy with Statins and Angiotensin ‐Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population‐Based Cohort Study in Korea
ConclusionA MACCE was less likely to occur in patients who received a statin ‐ARB than in those who received a statin‐ACEI. Similar trends were seen in cardiovascular mortality and the occurrence of recurrent MI but not stroke. The availability of statin‐ARB fixed‐dose combinations may have contributed to the improved outcomes in the statin‐ARB cohort by reducing p ill burden and improving medication adherence. Further research is warranted to validate our findings and to address whether a particular statin‐ARB combination is more effective than other combinations.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 6, 2018 Category: Drugs & Pharmacology Authors: Jimin Lee, Sukhyang Lee Tags: Original Research Article Source Type: research

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
This study provides a rationale for testing the lipoprotein(a) lowering hypothesis in cardiovascular disease outcomes trials.FundingNovartis Pharma AG.
Source: The Lancet - October 5, 2018 Category: General Medicine Source Type: research

Low LDL-C and risk of hemorrhagic stroke in Chinese adults
It is well-established that higher LDL and total cholesterol are associated with increased risk of atherosclerotic cardiovascular disease (ASCVD), that is, coronary heart disease (CHD) and ischemic stroke events, and that cholesterol-lowering by statins and other therapies reduce ASCVD risk. However, the picture is less clear for the 10% to 20% of strokes that are hemorrhagic rather than ischemic. A meta-analysis of observational studies shows that lower levels of LDL-C and total cholesterol are associated with higher risk of hemorrhagic strokes (HS), and with intracranial hemorrhage (ICH), a subset of HS.
Source: Journal of Clinical Lipidology - September 1, 2018 Category: Lipidology Authors: Rachel H. Mackey Tags: Editorial Source Type: research

Secondary CV Prevention in South America in a Community Setting: The PURE Study
ConclusionsThere are large gaps in the use of proven medications for secondary prevention of cardiovascular disease in South America. Strategies to improve the sustained use of these medications will likely reduce cardiovascular disease burden substantially.
Source: Global Heart - July 10, 2018 Category: Cardiology Source Type: research